IFF to Webcast Fireside Chat at Barclays Global Consumer Staples Conference on Sept. 4
13.8.2025 22:15:00 CEST | Business Wire | Press Release
IFF (NYSE: IFF) today announced that Chief Financial Officer Michael DeVeau will participate in a fireside chat at the Barclays Global Consumer Staples Conference on Thursday, Sept. 4, 2025 at 9 a.m. ET.
Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay.
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250813839035/en/
Contacts
Media Relations
Paulina Heinkel
332-877-5339
Media.request@iff.com
Investor Relations
Michael Bender
212-708-7263
Investor.Relations@iff.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nexpring Health Invests in May Health to Advance a Novel Technology to Treat PCOS-Related Infertility10.3.2026 13:00:00 CET | Press Release
Nexpring Health, a global leader in assisted reproductive technology (ART) solutions, today announced a strategic investment in May Health, a medical device company pioneering a novel treatment approach for women with polycystic ovary syndrome (PCOS)-related infertility. Nexpring Health joined May Health’s €10 million ($11.7M) financing round alongside investors including Sofinnova Partners, Trill Impact, and Bpifrance. This investment reflects Nexpring Health's commitment to driving meaningful innovation that moves the field of fertility care forward and goes beyond the products in the lab by supporting the innovations that redefine what’s possible for patients and the clinicians who serve them. Backing the Breakthrough That PCOS Patients Need PCOS is the most common endocrine condition among reproductive-aged women and a leading cause of female infertility, affecting an estimated 10–13% of women worldwide. 1,2 Women with PCOS-related infertility often struggle to become pregnant beca
Perion's AI Agent Outmax Now Available for TikTok, Delivering Up to 25% Greater Media Performance in Early Results10.3.2026 12:00:00 CET | Press Release
Perion Network Ltd. (NASDAQ and TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, today announced the launch of its proprietary Outmax AI agent for TikTok. This integration extends Perion’s capabilities to one of the fastest-growing global advertising platforms, with nearly 1.6 billion users worldwide and rapidly expanding advertiser adoption as brands increasingly prioritize TikTok in their media strategies. TikTok’s advertising revenue is expected to exceed $50 billion by 20271. Perion’s Outmax AI agent is embedded within Perion’s AI-native infrastructure, designed to increase advertiser efficiency and performance. Fully integrated with TikTok, Outmax applies algorithmic intelligence beyond native platform defaults, enabling advertisers to optimize against brand-defined business outcomes rather than platform-standard KPIs. The new Outmax for TikTok AI Model is already delivering up to 25% better
The KCAS Bio – Lyon, France Site Renews Its GLP Compliance Statement, Strengthening Its Support for IND-Enabling Studies Through Bioanalysis and Biomarkers10.3.2026 12:00:00 CET | Press Release
KCAS Bio today announced that its European site in Lyon, France, has successfully renewed its Statement of Compliance with Good Laboratory Practices (GLP) according to Directive 2004/9/CE (safety tests), confirming the site’s continued ability to deliver GLP-grade bioanalytical methods in support of preclinical studies. The GLP test facility once again earned a Level of Compliance “A,” reinforcing KCAS Bio’s capability to support critical investigational new drug (IND)-enabling programs. This renewal provides sponsors with continued confidence that their studies are supported by robust, compliant, and regulatory-ready bioanalytical data. This GLP renewal, combined with the site's ISO 9001:2015 certification, which has been maintained without interruption for more than 15 years, reflects the rigor, reliability, and consistency demonstrated by the scientific teams at the Lyon site in all projects throughout the drug discovery and development continuum. “Our renewed GLP compliance undersc
Reply: a New Study Shows that Agentic AI will Become a Strategic Alternative to Traditional Sourcing Models for 93% of Tech Leaders10.3.2026 11:26:00 CET | Press Release
Reply [EXM, STAR: REY] today announced the release of “From Code to Control: AI’s Takeover of Software Development Lifecycle”, a commissioned study conducted by Forrester Consulting. The research, which surveyed 536 IT Executives across Europe and the US, highlights the progressive transition from simple AI coding assistants to autonomous agents capable of orchestrating the entire software development lifecycle (SDLC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310922600/en/ Silicon Shoring is Reply’s delivery model designed to leverage this shift toward Agentic AI. By using the Silicon Reply multi-agent system, this methodology offers a robust alternative to traditional offshoring. The study underscores a critical turning point for software development: as traditional offshoring models struggle with hidden costs and regulatory hurdles, 93% of organisations plan to adopt Agentic AI within the next two to three years a
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel10.3.2026 11:00:00 CET | Press Release
WHOOP, the human performance company, today unveiled multiple initiatives and new clinically-backed features, including the coming launch of the company’s Women's Health Specialized Blood Biomarker Panel. Building on the WHOOP Advanced Labs Baseline Panel launched last year, the Women’s Health Specialized Blood Biomarker Panel adds 11 clinically backed, female-specific blood biomarkers that expand insight into areas that are frequently under-measured or misinterpreted in traditional women’s health testing. WHOOP has also announced a new Hormonal Symptom Insights and Predictions update, along with a comprehensive Menstrual Cycle White Paper detailing the science behind its cycle modeling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310966566/en/ WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel These initiatives reflect the company’s commitment to advancing women’
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom